Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Cardioxyl Pharma

- PMLiVE

Medscape Cardiology: Leading the Future of Heart Failure Education at HFSA 2025

Medscape Cardiology | theheart.org is proud to be at the forefront of the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM), September 26–29, 2025, in Minneapolis, MN! With...

Medscape Education

Bayer symbol

Bayer’s Kerendia granted FDA approval for new heart failure indication

Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

Bayer symbol

Bayer presents positive results for Kerendia in late-stage heart failure study

Approximately 55% of the 6.7 million heart failure patients in the US have an LVEF of at least 40%

- PMLiVE

J&J to expand cardiovascular capabilities with V-Wave acquisition worth up to $1.7bn

The company’s medtech division will gain access to a cardiovascular implant device for heart failure

Bayer symbol

Bayer shares promising results for Kerendia in phase 3 heart failure study

Approximately 55% of heart failure patients have an LVEF of at least 40%

- PMLiVE

Novo Nordisk to acquire cardiovascular disease specialist Cardior in deal worth over €1bn

The deal includes a candidate being evaluated in a mid-stage trial to treat heart failure patients

- PMLiVE

New blood test could identify individuals at highest risk of developing heart failure

Measuring NPY alongside BNP could help healthcare professionals improve diagnosis for heart patients

- PMLiVE

Hitting Every Beat—The Power of Education in Heart Failure

Heart failure can be a challenge to manage both for clinicians and patients. It’s a complex condition with various manifestations and presentations, and different disease stages that require different approaches...

Medscape Education

- PMLiVE

Bristol Myers Squibb’s subcutaneous Opdivo shows promise in kidney cancer

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

- PMLiVE

BMS announces CHMP recommendation for multiple myeloma therapy Abecma

More than 50,000 cases of the blood cancer are diagnosed in Europe every year

- PMLiVE

BMS, Exelixis and Ipsen announce positive four-year results for kidney cancer regimen

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

- PMLiVE

BMS presents promising late-stage results for Opdivo plus Yervoy in colorectal cancer

More than 1.9 million cases of colorectal cancer were diagnosed globally in 2020

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links